GlassScriptPhysician profile
Ziqiang Zhu
NPI 1477978286
$8,741.06
in general payments reported to CMS, 2019-2025
32 companies · $2,652 in 2025
The $2,652 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $275 · 2020: $434 · 2021: $489 · 2022: $774 · 2023: $2,014 · 2024: $2,102 · 2025: $2,652.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,757 · Education: $11.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,757.15 |
| Education | $11.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,651.22 | 2019-2025 | |
| Novo Nordisk INC | $838.48 | 2022-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $769.32 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $765.17 | 2024-2025 | Evenity, Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $662.22 | 2023-2025 | |
| Lilly USA, LLC | $508.58 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $476.31 | 2021-2025 | Creon, Linzess, Viberzi |
| Glaxosmithkline, LLC. | $468.13 | 2023-2025 | Arexvy, Shingrix |
| Phathom Pharmaceuticals, INC. | $405.25 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $323.45 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $207.45 | 2020-2023 | Steglatro, Belsomra |
| Astellas Pharma US INC | $191.76 | 2023-2024 | Veozah, Myrbetriq |
| Nestle Healthcare Nutrition INC. | $162.76 | 2021 | |
| Alexion Pharmaceuticals, INC. | $130.05 | 2025 | Ultomiris |
| Kite Pharma, INC. | $125.00 | 2023 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $125.00 | 2025 | Auvelity |
| Celgene Corporation | $125.00 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $124.90 | 2025 | Dupixent |
| Foundation Medicine, INC. | $116.67 | 2023 | |
| Vbi Vaccine (Delaware) INC. | $115.44 | 2022-2023 | Prehevbrio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.09 | 2024-2025 | Jardiance |
| Ardelyx, INC. | $64.81 | 2025 | Ibsrela |
| Phadia US INC. | $56.19 | 2020-2024 | Immunocap |
| Organon LLC | $54.98 | 2025 | Nexplanon |
| Amarin Pharma, INC. | $39.83 | 2022-2023 | |
| Insmed, INC. | $28.48 | 2023 | Arikayce |
| Agios Pharmaceuticals, INC. | $26.48 | 2025 | Pyrukynd |
| Agile Therapeutics, INC. | $22.72 | 2024 | Twirla |
| Pfizer INC. | $18.20 | 2024 | |
| Redhill Biopharma INC. | $17.30 | 2021 | |
| Hologic Sales and Service, LLC | $17.14 | 2024 | Aptima |
| Horizon Therapeutics Plc | $12.68 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ziqiang Zhu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.